RAC1 and colorectal carcinoma: Interestingly, inhibition of Rac1 by the 1A-116 compound decreases the growth of 5-FU-resistant CRC, sensitizes cells to 5-FU therapy, and prevents metastasis development, suggesting that therapies based on Rac1 inhibition could be of benefit to overcome therapy resistance.